AzTrials
AzTrials

Electronic Nicotine Delivery SystemsEXERVAPENCT06474962

Cardiorespiratory Fitness and Health Parameters in E-cigarrete Users: Impact of a Short Term Pause in Consumption

A study testing Pause in people with Electronic Nicotine Delivery Systems, run by University of Sao Paulo at 1 site in Brazil.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Goal: Investigate the health effects of electronic cigarettes (e-cigarettes) and whether a short break from using them can improve health. Participants: Up to 148 people (74 who use e-cigarettes and 74 who don't) Age and sex will be matched between the groups. Read more about this study

Who is it for?
Ages 14 years and olderHealthy volunteers can take part
Conditions the study is for
Electronic Nicotine Delivery Systems
What is being tested?
Pause
Could I receive a placebo?
No, everyone receives an active treatment
How many people
148 participants
Where
1 siteBrazil
Study dates
Jun 2024to Apr 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 14 years and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • 14 years of age or older
  • Reporting using nicotine electronic cigarettes (e-cigarettes)
  • Serum cotinine levels equal to or greater than 3 ng/mL

Who cannot join

  • Contraindications for maximum exercise testing or any of study procedures
  • Use of any smoking product except e-cigarette (combustible cigarette, cigar, hookah, marijuana, etc.)

Trial locations and contacts

1 site in 1 country.

Bruno Gualano, PhD contact

551126618022

gualano@usp.br

Lucas Porto Santos, PhD contact

5551999636177

lucaspsantos87@gmail.com

Brazil1 site
  • Clinical Hospital of the School of Medicine, University of Sao Paulo

    São Paulo, 05403-000

Other trials in Brazil

About this study

Goal: Investigate the health effects of electronic cigarettes (e-cigarettes) and whether a short break from using them can improve health.

Participants:

Read more

Up to 148 people (74 who use e-cigarettes and 74 who don't) Age and sex will be matched between the groups.

Study Design:

Two connected studies:

Observational Study: Compares general health (including lung function, heart health, blood pressure, and inflammation) of e-cigarette users to non-smokers.

Clinical Trial: E-cigarette users will be randomly assigned to either:

Take a 7-day break from e-cigarettes (intervention group) Continue using e-cigarettes as usual (control group) Both groups will have their health measured before and after the 7-day period. Main Outcome: How well your heart and lungs work during exercise.

Other Outcomes: Lung function, blood vessel function, risk factors for heart disease, and body measurements.

Why is this study important?

E-cigarettes are becoming more popular, but their health effects are unknown. This study will provide new information on whether e-cigarettes harm your health and if quitting for a short time can improve it.

This information can be used to create better public health policies about e-cigarettes.

Read the detailed description

The emergence of electronic smoking devices is a recent and scientifically underexplored phenomenon. These devices were initially thought of as a harm-reduction strategy in cigarette smokers, a purpose for which there is still no definitive evidence of effectiveness. Preliminary but consistent findings in the literature suggest the possibility of detrimental health effects to e-cigarette users. Despite being prohibited for sale in the country, electronic cigarettes are easily accessible, in an unregulated manner. The increasing number of users, approaching one million according to recent data, and the uncertainties regarding the composition, manufacturing quality, and potential long-term effects of exposure to the vapor they produce, make the use of electronic cigarettes an emerging issue in Brazilian public health. Based on the aforementioned issues, exploring the potential effects of this new health-related behavior is urgent. Thus, the present proposal describes a research project envisioning the execution of two interconnected studies: (1) an observational cross-sectional analysis, in an exposed-control design, evaluating general health parameters of electronic cigarette users compared to non-smoking control individuals, matched by sex and age; and (2) an intervention study nested within the first study, designed as a randomized clinical trial, with electronic cigarette users assigned to a group that will take a 7-day pause from using these devices, compared to a control group that will not undergo any intervention. The studies were designed with cardiorespiratory fitness - measured by a maximum exercise cardiopulmonary test (ergospirometry) - as the primary outcome. The sample size calculated for the cross-sectional study comprises 148 individuals (74 per group), and the intended sample for the randomized clinical trial consists of the 74 electronic cigarette users already recruited for the cross-sectional study. The secondary outcomes of both studies are related to cardiorespiratory parameters, pulmonary function (spirometry), vascular function (endothelial function and tissue oxygenation), cardiovascular risk (lipid profile and blood pressure), inflammatory markers, and anthropometric measurements. The statistical analyses will be performed using Analysis of Covariance (ANCOVA), with physical activity level as a covariate for the cross-sectional study, and Generalized Estimating Equations (GEE), with initial oxygen consumption value as a covariate for the clinical trial. The investigators expect that the proposed studies yield new and relevant information regarding the potential harmful effects of electronic cigarettes, as well as the possibility of reversing these effects through refraining from their consumption. The novelty of the studies, the urgency of the topic, the boldness of the experimental approaches, and the high immediate applicability of the findings are highlighted in this proposal, with the potential to support public health policies concerning this relevant issue.

Being tested
Pause
Keywords
vaping, e-cigarette
Medical subject headings
Vaping

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PauseBehavioural

    7 days of no e-cigarette consumption

Study groups in NCT06474962
Study groupRoleWhat they receive
PauseExperimentalIndividuals will attempt to halt e-cigarette consumption for 7 days
Receives: Behavioral: Pause
ControlNo interventionIndividuals will continue habits as usual

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximal oxygen consumption

    Maximal cardiorespiratory fitness assessed in a treadmill test

    Measured: Baseline

  2. Maximal oxygen consumption

    Maximal cardiorespiratory fitness assessed in a treadmill test

    Measured: 7 days

Secondary outcomes (13)
  1. Pulmonary function

    Assessed through spirometry analysis of flow volume loops patterns

    Measured: Baseline

  2. Pulmonary function

    Assessed through spirometry analysis of flow volume loops patterns

    Measured: 7 days

  3. Endothelial function

    Assessed through ultrasonography of brachial artery

    Measured: Baseline

  4. Endothelial function

    Assessed through ultrasonography of brachial artery

    Measured: 7 days

  5. Lipid profile

    Blood concentrations of HDL cholesterol, LDL cholesterol, total cholesterol and tryglicerides

    Measured: Baseline

  6. Lipid profile

    Blood concentrations of HDL cholesterol, LDL cholesterol, total cholesterol and tryglicerides

    Measured: 7 days

  7. Health-related quality of life

    Assessed through "Short-form 36" questionnaire

    Measured: Baseline

  8. Health-related quality of life

    Assessed through "Short-form 36" questionnaire

    Measured: 7 days

  9. Anxiety symptoms

    Assessed through Beck's Anxiety Inventory

    Measured: Baseline

  10. Anxiety symptoms

    Assessed through Beck's Anxiety Inventory

    Measured: 7 days

  11. Blood pressure

    Office blood pressure measured with automated oscillometric device

    Measured: Baseline

  12. Inflammatory status

    Measured by blood concentration of inflammatory markers: interleukins 6 and 10, interferon-gamma, c-reactive protein and tumoral necrosis factor alpha

    Measured: Baseline

  13. Inflammatory status

    Measured by blood concentration of inflammatory markers: interleukins 6 and 10, interferon-gamma, c-reactive protein and tumoral necrosis factor alpha

    Measured: 7 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jun 2024
  2. Study startJun 2024 (estimated)
  3. Primary completionApr 2026 (estimated)
  4. Study completionApr 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
148 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06474962
Sponsor's protocol ID
71092523.7.0000.0068
Acronym
EXERVAPE
Status last verified
Jun 2024
First submitted
4 Jun 2024
Last updated
26 Jun 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be shared in accordance with institutional and legal requirements and will be provided upon reasonable request.

Questions about this trial

What is this clinical trial studying?

A study testing Pause in people with Electronic Nicotine Delivery Systems, run by University of Sao Paulo at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 26 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Bruno Gualano, PhD (551126618022, gualano@usp.br), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximal oxygen consumption (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in